Risedronic acid

Also known as: Risedronate sodium

Active ingredient description

Risedronic acid is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Risedronic acid
M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA07

Medicines

Risedronic acid is the active ingredient of these drugs:

Drug
Countries

Germany

Spain

Australia

Hong Kong

Australia Austria Brazil Canada Cyprus

Tunisia

Spain

Cyprus

Cyprus

Italy

Brazil

Brazil

Italy

Cyprus Lithuania

Lithuania Poland

Finland Italy

Tunisia

Brazil

Brazil

Hong Kong

Italy

Italy

Italy

Brazil

Italy

Lithuania Poland

Ireland Lithuania

Brazil

Tunisia

Italy

Italy

Italy

Italy

Poland

Risedronic acid is also found within below combination drugs:

ACARA TRIO , ACRIS COMBI , ACTONEL COMBI , ACTONEL PLUS CALCIUM & D , ATELVIA , OPTINATE PLUS CA & D , RIDATE PLUS CA & D

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

KM2Z91756Z - RISEDRONIC ACID

CAS registry number

105462-24-6 - risedronic acid

115436-72-1 - Sodium risedronate

SNOMED-CT

105590001 - Substance (substance)

768539002 - Risedronic acid (substance)